Pradžia › Mielofibrozė › Texas
Mielofibrozė klinikiniai tyrimai Texas
20 tyrimai dėl Mielofibrozė ieško dalyvių vietose Texas.
Miestai Texas
Oficialus tyrimo tekstas (anglų kalba)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- MD Anderson Cancer Center, Houston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT04176198A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- Texas Oncology PA Dallas Presbyterian Hospital, Dallas
- MD Anderson Cancer Center, Houston
- SCRI Texas Oncology Northeast Texas, Tyler
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT07357727A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- The University of Texas, MD Anderson Cancer Center, Houston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT07469891A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Baylor University Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- The University of Utah-Huntsman Cancer Institute, Houston
- ir dar 1
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT07623161Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- MD Anderson, Houston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT05320198A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- MD Anderson Cancer Center, Houston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT06343805High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
- MD Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-16 · NCT06345495A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- South Austin Medical Center, Austin
- University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood, Dallas
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-06 · NCT07008118Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- University of Texas M. D. Anderson Cancer Center, Houston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-22 · NCT07441694Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
- The University of Texas M. D. Anderson Cancer Center, Houston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-15 · NCT07128381Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
- MD Anderson Cancer Center, Houston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-26 · NCT06327100Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- MD Anderson Cancer Center, Houston
Renkami dalyviai1 fazė
Amžius 13 ir vyresni · Visoms lytims · Atnaujinta 2026-05-05 · NCT04771572Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
- GSK Investigational Site, Houston
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-20 · NCT06517875A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Md Anderson Cancer Center, Houston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-17 · NCT06034002A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- MD Anderson, Houston
Renkami dalyviai2 fazė
Amžius nuo 18 iki 66 · Visoms lytims · Atnaujinta 2026-03-17 · NCT06859424A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- MD Anderson, Houston
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-12 · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2025-10-28 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- UT - SouthWestern, Dallas
- U.T. MD Anderson Cancer Center, Houston
- The University of Texas Health Science Center at San Antonio, San Antonio
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-09-25 · NCT06479135Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
- The University of Texas MD Anderson Cancer Center, Houston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-04-13 · NCT05423691Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
- The University of Texas MD Anderson Cancer Center, Houston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2023-02-21 · NCT05280509Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.